Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21243943 | 0.91 | KIT (0.37) | KRASKITTP53PIK3CAMTOR | |
| SCHEMBL21243930 | 0.89 | MAPT (0.39) | KRASMAPTLMNATP53PIK3CA | |
| SCHEMBL30834490 | 0.89 | KRAS (0.52) | KRAS | |
| SCHEMBL21733673 | 0.89 | KRAS (0.52) | KRAS | |
| SCHEMBL21243863 | 0.86 | KRAS (0.38) | KRASMAPTLMNATP53PIK3CA | |
| SCHEMBL30834509 | 0.86 | KRAS (0.41) | KRASATR | |
| SCHEMBL21733669 | 0.86 | KRAS (0.41) | KRASATR | |
| SCHEMBL25248755 | 0.85 | MAPT (0.36) | KRASMAPTLMNATP53PIK3CA | |
| SCHEMBL30305242 | 0.85 | MAPT (0.36) | KRASMAPTLMNATP53PIK3CA | |
| SCHEMBL25253665 | 0.84 | GPR119 (0.39) | KRASMAPTLMNATP53PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749665-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Inc. (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
| WO-2019155399-A1 | TETRAHYDROQUINAZOLINE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | TOP2A, TOP1, TOP2B | KRAS 149/4885KIT 793/4885MAPT 2604/4885 |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | TOP2A, TOP1, TOP2B | KRAS 149/4885KIT 793/4885MAPT 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.